Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: A randomised controlled trial

Gut

Volumn 55, Issue 9, 2006, Pages 1290-1295

  Tripathi, D ^a   Therapondos, G ^a   Ferguson, J W ^a   Newby, D E ^a   Webb, D J ^b   Hayes, P C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

ADULT; AGED; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; PULMONARY CIRCULATION; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 33747811193     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.077453     Document Type: Article

References (36)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
2. Masaki T, Yanagisawa M, Goto K. Physiology and pharmacology of endothelins. Med Res Rev 1992;12:391-421.
3. La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 1995;22:315-23.
4. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996;93:1860-70.
5. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-8.
6. Kapoor D, Redhead DN, Hayes PC, et al. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003;9:32-9.
7. Hartleb M, Kirstetter P, Moreau R, et al. Relationships between plasma endothelin concentrations and the severity of cirrhosis. Gastroenterol Clin Biol 1994;18:407-12.
8. Mollier S, Gulberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in cirrhosis - relations to systemic and splanchnic hemodynamics. J Hepatol 1995;23:135-44.
9. Yokomori H, Oda M, Yasogawa Y, et al. Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver. Am J Pathol 2001;159:1353-62.
10. Leivas A, Jimenez W, Bruix J, et al. Gene expression of endothelin-1 and ETA and ETB receptors in human cirrhosis: Relationship with hepatic hemodynamics. J Vasc Res 1998;35:186-93.
11. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-51.
12. De Gottardi A, Shaw S, Sagesser H, et al. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats. J Hepatol 2000;33:733-7.
13. Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020-30.
14. Kojima H, Sakurai S, Kuriyama S, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001;34:805-11.
15. Sogni P, Moreau R, Gomola A, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-9.
16. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-4.
17. Helmy A, Newby DE, Jalan R, et al. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410-15.
18. Rolinski B, Sadri I, Bogner J, et al. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med (Berl) 1994;194:9-24.
19. Caesar J, Shaldon S, Chiandusi L, et al. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961;21:43-57.
20. Spratt JC, Goddard J, Patel N, et al. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001;134:648-54.
21. Strachan FE, Spratt JC, Wilkinson IB, et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999;33:581-5.
22. Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
23. Leevy CM, Mendenhall CL Lesko W, et al. Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962;41:1169-79.
24. Helmy A, Jalan R, Newby DE, et al. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001;33:826-31.
25. Chan CC, Wang SS, Lee FY, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001;33:816-20.
26. Bohm F, Pernow J, Lindstrom J, et al. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in me splanchnic and renal circulation of healthy men. Clin Sci 2003;104:143-51.
27. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
28. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
29. Rubin U, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
30. Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003;52:1355-02.
31. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8.
32. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-31.
33. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-93.
34. Leslie SJ, Spratt JC, McKee SP, et al. Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart 2005;91:914-19.
35. Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996;25:909-15.
36. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6.